Blog

10 July, 2024

Medicines as a strategic asset

EL PAÍS and Farmaindustria address the tasks pending to achieve autonomy in the manufacture of pharmaceuticals. Elpais.com Spain stands out for its strong pharmaceutical industry. It […]
9 July, 2024

SemFYC and Farmaindustria collaborate to promote clinical trials in Primary Care

A hundred members of the Spanish Society of Family and Community Medicine and pharmaceutical companies attend a training session to learn about the opportunities offered to […]
25 June, 2024

Farmaindustria promotes its project to increase clinical research in primary care in the autonomous communities of Spain.

After its presentation a few months ago in Andalusia, the guide to bring clinical trials to health centres has been disseminated in Castilla y León and […]
17 June, 2024

Latin American countries interested in the successful model of clinical trials in Spain promoted by Farmaindustria

The Association has participated in the Forum on clinical trials organised by the United Nations in the Latin American and Caribbean region together with the Latin […]
23 May, 2024

THESE ARE THE 10 REASONS WHY SPAIN IS A WORLD LEADER IN CLINICAL TRIALS

Spain is a benchmark country in the world and the first in Europe to conduct clinical trials to test the safety and efficacy of new drugs. […]
15 May, 2024

The European Health Technology Assessment Regulation, an opportunity to speed up access to new medicines for patients in Spain

Its application should also serve to put an end to repetitive and inefficient evaluations and guarantee rigour for patients and healthcare professionals, who will play an […]
13 May, 2024

Farmaindustria launches Jóvenes en Farma, a web space to raise awareness of job opportunities in the sector and connect junior talent with companies

Recruitment forecasts for innovative pharmaceutical companies for the coming years exceed 10,000 new jobs for the under-30s. The website offers practical information about the sector and […]
30 April, 2024

Precision medicine and new medicines require the modernisation of evaluation and funding processes, including the social perspective and the economic contribution to the country.

Funcas and Farmaindustria held a conference on ‘The economic regulation of the pharmaceutical industry. Current situation and future prospects in Spain’, which was attended by more […]
24 April, 2024

Spain, a clinical trials powerhouse

Spain is at the forefront of research. Experts discuss the potential of new medicines at a forum organised by EL PAÍS and Farmaindustria. Elpais.com In the […]
22 April, 2024

Innovation as a patients’ right

DemócrataPRO brings together the Health Commission to debate on the reform of the law on medicines On 21 March, DemócrataPro brought together the spokespersons of the […]
3 April, 2024

Technology and Innovation Platforms, key elements of Spain’s R&D&I system

The Spanish Technological Platform for Innovative Medicines, led by Farmaindustria, has been promoting public-private collaboration projects in clinical and pre-clinical research since 2005. “Spain currently occupies […]
2 April, 2024

HPV: THE SUCCESS OF A VACCINE TO PREVENT CANCER AND WHY IT IS IMPORTANT TO SPREAD IT WORLDWIDE

Human papillomavirus is responsible for 95% of cervical tumours. Since 2006, several vaccines have been licensed that can prevent most cases. In Spain, the autonomous communities […]
19 March, 2024

The health sector, essential for the well-being of the population and an economic engine for society

fundacionidis.com The ecosystem of the private healthcare sector transcends the field of healthcare and has an impact on society and on the productive sectors of the […]
7 March, 2024

Spain takes, on average, two years to approve a drug for a minority disease

There are 146 orphan drugs approved by the European Medicines Agency. Spain has only 81 in its catalogue. It has rejected funding for 25 and is […]
5 March, 2024

22% of clinical trials underway in Spain seek new treatments for rare diseases

Research into new drugs for rare diseases has multiplied in recent years. In Spain, industry drives 90% of clinical trials for this type of disease. One […]
13 February, 2024

The Andalusian Regional Government and Farmaindustria will promote R&D&I in health with a special focus on the promotion of clinical trials.

In a press release, the Andalusian Regional Government highlights the joint commitment of both entities to continue advancing in the promotion of R&D&I, following the meeting […]
8 February, 2024

Spain is the country with the highest participation in clinical trials of new drugs in Europe

Of the 1,944 clinical trials authorised in the European Union through the new European Information System, Spanish centres participated in 845, or 43% of the total. […]
6 February, 2024

Europe calls latest cancer drugs “significant progress” for health

The European Medicines Agency has thus identified nine oncology approvals for 2023. The arrival of new treatments is directly linked to the pharmaceutical industry’s commitment to […]
2 February, 2024

The Innovative Medicines Platform sets its roadmap for 2024 with the aim of turning Spain into a major biomedical innovation hub

The Technological Platform for Innovative Medicines – whose Coordination Committee is made up of 10 representatives from the pharmaceutical industry and 10 representatives from public research […]
1 February, 2024

A common catalogue of biomarkers in the National Health System is a great step forward for patients because it improves access to personalised medicine.

Farmaindustria welcomes the presentation by the Ministry of Health of the harmonised catalogue of genetic tests for the whole country. For this catalogue to become a […]
30 January, 2024

Frank R. Lichtenberg, Professor at Columbia University: “Life expectancy of cancer patients in Spain has increased by almost three years in the last decade thanks to the use of innovative drugs”.

The US expert unpacked the data from his study on the relationship between pharmaceutical innovation and cancer mortality in Spain between 1999 and 2016 in a […]
15 January, 2024

FDA approves 55 new drugs in 2023, one of the highest numbers in a decade

Infectious diseases, neurological diseases, type 2 diabetes in children, oncology and cardiac disorders are just some of the areas that benefited from the innovation drive last […]
11 January, 2024

The Distefar team is environmentally conscious and switches from buying single-use plastic bottles to glass bottles.

8 January, 2024

The pharmaceutical industry, a strategic sector for Spain and Europe

“We are the industrial area that invests the most in R&D, a productive and exporting engine”. larazon.es Developing and producing new medicines for society is both […]
21 December, 2023

Paediatricians join project to boost clinical research in primary care

The working group led by Farmaindustria holds a new meeting, with the participation of two new pharmaceutical companies. Farmaindustria.es The drive for clinical research in Primary […]
19 December, 2023

R&D investment in the pharmaceutical industry reaches 1.4 billion euros in Spain and grows by 10% in just one year

Of the €1.395 billion registered in 2022, 60% was devoted to clinical trial development. One out of every eight euros is already spent on basic and […]
11 December, 2023

“The European Health Data Space is an opportunity to gain greater efficiency in cancer drug research”.

Farmaindustria participates in the Medical Oncology, Haematology and Oncohaematology Pharmacy Congress ‘Building Bridges’, where data management in biomedical research was discussed. Farmaindustria.es “The proposed Regulation for […]
1 December, 2023

“Clinical trials are a hope for patients with rare diseases and already account for 25% of all research done in Spain”.

Farmaindustria’s CEO, Juan Yermo, participates in the conference ‘Towards a Comprehensive European Plan: Spain’s involvement with Rare Diseases’, organised by Feder in the Spanish Congress of […]
27 November, 2023

Boosting clinical research in Primary Care, an opportunity for patients, professionals and the health system

Farmaindustria presents the ‘Guide of good practice recommendations for the promotion of clinical research in Primary Care’, which will bring new treatment opportunities to patients in […]
21 November, 2023

“The European Health Data Space is a unique opportunity that will improve research and innovation for the whole of society.

The director of Farmaindustria’s Research Department participates in a round table on the regulation of this project held at the European Parliament Office in Madrid. “For […]
3 December, 2024

Farmaindustria highlights the ‘paradigm shift’ of AI in biomedical research

The head of Innovation and director of Innovation at Farmaindustria, Miguel González, highlighted how Artificial Intelligence (AI) has brought about a paradigm shift and a revolution […]
20 November, 2024

The impact of the innovative pharmaceutical industry in Europe: 46.2 billion euros of R&D investment and the creation of more than 2.3 million jobs

A report by PwC for the European Federation of the Pharmaceutical Industry shows that the pharmaceutical industry contributes an economic value to the EU of 311,000 […]
18 November, 2024

Public investment in medicines remains stable in terms of GDP, which reinforces the idea of long-term financial sustainability.

Farmaindustria presents ‘The pharmaceutical industry and its context in Spain 2024’, the first report that brings together in a single volume all the figures of the […]
15 November, 2024

Advances the strategy to promote clinical trials in primary care centres, which will bring new treatment opportunities to patients in Spain.

One year after the presentation of the ‘Guide of good practice recommendations for the promotion of clinical research in primary care’, promoted by Farmaindustria, successful initiatives […]
12 November, 2024

‘Good implementation of pharmacogenomic markers will optimise the use of medicines and improve health outcomes’.

Arantxa Sancho, director of the Department of Medical-Scientific Affairs at Farmaindustria, participates in the informative seminar on pharmacogenomic biomarkers organised by the Aemps. Farmaindustria.es On 29 […]
5 November, 2024

Farmaindustria connects eight research projects from Spanish universities and small companies with 15 representatives from pharmaceutical companies

The Farma-Biotech programme facilitates the efficient exchange of information and personal knowledge between research groups, small spin-off companies and the pharmaceutical industry. Since its inception in […]
31 October, 2024

Open doors for research

Farmaindustria is leading a project to bring clinical trials to primary care to help decentralise this strategy. laopiniondezamora.es ‘Transforming primary care through clinical trials’ was the […]
29 October, 2024

New report on clinical trials places Spain as a leader and success story in Europe

Assessing Europe’s clinical trial ecosystem, produced by Iqvia for Efpia and Vaccines Europe, shows a 22-12% drop in the share of studies on the continent over […]
24 October, 2024

Fina Lladós, new president of Farmaindustria: ‘I will work to generate confidence and make the industry strategic in the economic and social development of Spain’.

The Extraordinary General Assembly on Thursday unanimously elected the CEO of Amgen Iberia to lead the Association for the next two years. Source: Farmaindustria.es Fina Lladós […]
22 October, 2024

Spain advances in paediatric clinical research through international projects based on public-private partnerships

There are currently more than 600 clinical trials underway for children and adolescents in Spain, almost half of them focused on rare diseases. The Spanish Network […]
8 October, 2024

Health sector awaits upcoming regulatory changes: ‘It’s a critical time’.

The closing table of the 5th Symposium of the Healthcare Observatory reviewed the challenges facing the sector. Spain, as a leader of a European health policy’. […]
27 September, 2024

Europe streamlines access to clinical trial information

The Clinical Trials Information System (CTIS), managed by the European Medicines Agency (EMA), is a single entry point for the submission and assessment of clinical trial […]